Clinical Trial Update: Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose [Phase 1]

View source ↗

Summary

Phase 1 trial update examining the effects of a 375 mg dose of aprepitant (Emend) in HIV-infected individuals; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Aprepitant (Emend) (aprepitant)

Snippet

Sponsor: University of Pennsylvania | Conditions: HIV Infection | Phase 1 | Status: COMPLETED